Rory Curtis PhD
VP, US Commercial Operations
Rory has 30 years’ experience in drug discovery and development with a focus on ion channels as drug targets.
He received his PhD in Biochemistry from Imperial College of Science, Technology and Medicine in London in 1991 and spent 25 years in industry with increasing levels of responsibility at Regeneron, Millennium, Elixir and Cubist Pharmaceuticals. At Millennium, Rory was responsible for ion channel drug discovery from identifying new ion channels through functional studies and HTS. At Cubist, he led the discovery and development of TRPA1 inhibitors, including Phase I clinical trials of CB-625, as well as early-stage discovery for Nav1.7 and other ion channel targets.
Rory spent the last 6 years in contract research operations and sales. He held leadership roles with AMRI (now Curia) and established the integrated drug discovery site in Buffalo, NY, before taking a business development role with the Hauptman-Woodward Institute.
Let’s work together
What are your specific ion channel and assay needs?
If you have any questions or would like to discuss your specific assay requirements, we will put you directly in touch with a member of our scientific team. Contact us today to discover more.